Antimicrob Agents Chemother YAO B-F, Yang Y, Xu S-S, Tang B-H, et al Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir. Antimicrob Agents Chemother. 2025 Sep 18:e0061425. doi: 10.1128/aac.00614. PubMed Abstract available LODISE TP, Min J, Nathanson BH, Yucel E, et al Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR Pseudomonas aeruginosa (PUMA). Antimicrob Agents Chemother. 2025;69:e0056925. PubMed Abstract available DE LA PORTE DES VAUX C, Veyrenche N, Silva KD, Chavarot N, et al Immunocompromised patients with persistent SARS-CoV-2 viral shedding >/=8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020-2024. Antimicrob Agents Chemother. 2025 Sep 26:e0065825. doi: 10.1128/aac.00658....